Due to the ongoing shortage of multiple strengths and presentations of oral cefalexin medicines we have extended the Therapeutic Goods (Serious Scarcity and Substitutable Medicine) (Cefalexin) Instrument 2023 (SSSI). This instrument allows pharmacists to substitute different strengths of cefalexin oral liquid based on stock availability, using a patient’s existing prescription.
The current SSSI was due to expire on 31 October 2023 and has been extended by the Therapeutic Goods (Serious Scarcity and Substitutable Medicine) (Cefalexin) Amendment Instrument 2023. The SSSI will remain in force until 30 April 2024 and continues to assist with timely access for patients using oral cefalexin syrups and suspensions.
Our About the shortage of oral cefalexin page contains comprehensive information about the new SSSI and the shortage for pharmacists, prescribers, and patients.